UNSPSC 51332857: Mesoridazine benzenesulfonate

This classification denotes a dopamine antagonist and antipsychotic agent with the molecular formula C21H26N2OS2.C6H6O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T4G2I958J2, chemically known as 10h-phenothiazine, 10-(2-(1-methyl-2-piperidinyl)ethyl)-2-(methylsulfinyl)-, (+/-)-, monobenzenesulfonate, but more generally known as mesoridazine benzenesulfonate, which bears US NIH Compound Identifier 36207.

European Medicines Agency schedules mesoridazine benzenesulfonate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08786MIG. Most nations, for tariff purposes, schedule mesoridazine benzenesulfonate under HS 29343090. SMILES: CN1CCCCC1CCN2C3CCCCC3SC4C2CC(CC4)[S+](C)[O-].C1CCC(CC1)S(=O)(=O)O.

UNSPSC 51332857 Mesoridazine benzenesulfonate is a Commodity code for a specific pharmaceutical product, but the recent state and local procurement activity tagged under it does not align with mesoridazine acquisition. The single recent opportunity on record—Seminole County, Florida's IFB 60459723LAS—solicits naloxone and drug deactivation systems for community health initiatives, not mesoridazine or related antipsychotic medications. This mismatch suggests either a tagging error in the opportunity database or that the code is used to aggregate broader pharmaceutical and medical-supply procurement that extends beyond its nominal product scope.

The Seminole County opportunity, posted June 30, 2026 with a response deadline of July 26, 2023, requires annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems delivered quarterly to the Seminole County Community Health Building in Sanford, Florida. The county solicited bids through its e-Procurement Portal on an IFB basis, with vendors required to include shipping and delivery costs, maintain drug-free workplace certification and E-Verify compliance, and carry workers' compensation and commercial general liability insurance. The contract offers a two-year initial term with a one-year renewal option and includes a three-month probationary termination period. The procurement shows no explicit set-aside designations for disadvantaged enterprises and may draw FEMA funding, triggering Clean Air Act and Federal Water Pollution Control Act compliance. No other state or local opportunities appear in the record under this code. Given the narrow activity and the disconnect between the code's name and the actual work being solicited, this code shows little relevant recent activity for firms pursuing mesoridazine-related pharmaceutical supply.